Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles:
Related suggestion:
Biden says Brown v. Board of Education ruling was about more than educationNadal returns to Roland Garros to practice amid doubts over fitness and formAnalysis: Larson enters conversation with Verstappen as best drivers in the worldSix killed in a 'foiled coup' in Congo, the army saysThe unstoppable duo of Emma Stone and Yorgos LanthimosWho is Jacob Zuma, the former South African president disqualified from next week's election?What's next for Iran after death of its president in crash?Hall of Fame outfielder Ken Griffey Jr. to lead Indianapolis 500 field in Corvette pace carShooting injures 2 at Missouri high school graduation ceremony'The Apprentice,' about a young Donald Trump, premieres in Cannes
2.173s , 4666.8203125 kb
Copyright © 2024 Powered by Lilly rides Mounjaro, Zepbound to better ,Earthly Echo news portal